Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nonacog Beta→

Nonacog Beta Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~55000 g/mol
Drug class
Recombinant coagulation factor IXantihaemorrhagic biologic
Mechanism of action
Replaces deficient factor IX in the intrinsic coagulation pathway. Activated factor IX, together with activated factor VIII, activates factor X, supporting thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency), including perioperative management, where the corresponding recombinant factor IX product is authorised.

Sources: https://www.medicines.org.uk/emc/product/11038/smpc · https://www.pfizerpro.in/medicine/benefix/about/mechanism-of-action · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nonacog Beta Environmental Risk Assessment (ERA) (the Nonacog Beta ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.